Henry Schein (NASDAQ:HSIC) Stock Rating Upgraded by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other research firms also recently weighed in on HSIC. Morgan Stanley reissued an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Mizuho reduced their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. UBS Group reissued a “neutral” rating and set a $89.00 target price (up from $85.00) on shares of Henry Schein in a research note on Tuesday, July 28th. Finally, BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Thursday, June 11th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $89.36.

Henry Schein Stock Performance

NASDAQ HSIC opened at $85.75 on Friday. The business’s 50-day moving average price is $82.19 and its two-hundred day moving average price is $78.30. Henry Schein has a 12 month low of $61.94 and a 12 month high of $89.34. The firm has a market capitalization of $9.77 billion, a PE ratio of 25.91, a price-to-earnings-growth ratio of 1.65 and a beta of 0.80. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm’s revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein will post 5.32 EPS for the current year.

Insider Activity

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.89% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein in the second quarter worth $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein during the 2nd quarter worth about $27,000. Flagship Harbor Advisors LLC bought a new position in shares of Henry Schein during the 4th quarter worth about $30,000. Federated Hermes Inc. acquired a new stake in shares of Henry Schein in the 4th quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Henry Schein in the 4th quarter valued at about $37,000. 96.62% of the stock is owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.